Condition: Lymphoma · Waldenström Macroglobulinemia (WM) · DLBCL - Diffuse Large B Cell Lymphoma · Sponsor: ModeX Therapeutics, An OPKO Health Company
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
This description comes directly from the study's public registry record.
ModeX Therapeutics, An OPKO Health Company · +1 857-233-9936 · info@modextx.com
Always discuss trial participation with your own doctor first.
| Epworth HealthCare | Richmond, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07249905